Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 10:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 3,875 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Type 2 Diabetes Mellitus
Interventions: LY3209590, Insulin Degludec; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 31
States / cities: Sheffield, Alabama • Huntington Park, California • Los Angeles, California + 26 more

Conditions: Healthy, Young Adults
Interventions: RLIC - 5 cycles, RLIC - 4 Cycles, RLIC - 3 Cycles, Sham conditioning, Balance training, Arm training, Sequence production training; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 40 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Acute Lymphoblastic Leukemia
Interventions: Gross Motor Function, Knee extension strength, Hand grip strength, Flexibility, Ankle range of motion, Aerobic capacity, Body composition and vital signs; Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 5 Years to 10 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 4
States / cities: Portland, Oregon • Philadelphia, Pennsylvania • Memphis, Tennessee + 1 more

Conditions: Chronic Kidney Disease
Interventions: Vadadustat; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 2
States / cities: Saint Paul, Minnesota • Knoxville, Tennessee

Conditions: Healthy
Interventions: [¹⁴C]-LY3484356, LY3484356, [¹⁴C]-LY3484356 (IV); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Appendicitis, Evidence of Cholecystectomy, Gallstones, Pregnancy, Ectopic, Aortic Aneurysm, Kidney Stones, Intrauterine Pregnancy, Diverticulitis, Abdominal Injuries, Tumors, Pancreatitis, Digestive System Diseases, Gastrointestinal Diseases, Intraabdominal Infections, Intestinal Diseases, Pregnancy, Vascular Disease, Uterine Fibroids, Ovarian Cysts, Uterine Abnominalies, Bladder Abnominalies, Testicular Abnominalies, Polyps
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 174 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Prostatic Neoplasms
Interventions: MK-5684, Prednisone, Fludrocortisone acetate, Diltiazem hydrocholoride; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Acute Myocardial Infarction
Interventions: Not listed
Lead sponsor: Hennepin County Medical Center, Minneapolis; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Pain
Interventions: Codeine Sulfate; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hyperglycemia, Diabetes Mellitus
Interventions: Lantus® (insulin glargine); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2002
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Suicidal Ideation, Suicide Attempt
Interventions: CAMS Single Session Consultation, Driver Focused Skills Training, Caregiver Skills Training, Lethal Means Safety; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 13 Years to 21 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HCV Infection
Interventions: placebo, GS-9190, Peginterferon Alfa 2a, Ribavirin; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 48
States / cities: Anaheim, California • Los Angeles, California • Newport Beach, California + 37 more

Conditions: Epilepsies
Interventions: Rapid Titration VNS programming, Standard VNS programming; Device
Lead sponsor: Fernando Vale; Other
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Cardiovascular Diseases
Interventions: Lipid Challenge; Dietary Supplement
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Infertility, Egg Freezing
Interventions: Oocyte Vitrification; Procedure
Lead sponsor: University Reproductive Associates; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Hasbrouck Heights, New Jersey

Conditions: Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, Supratentorial Glioblastoma, Supratentorial Gliosarcoma
Interventions: P140K-MGMT, O6-benzylguanine, Photon Based Radiotherapy, temozolomide, Filgrastim, carmustine; Biological · Drug · Radiation
Lead sponsor: Leland Metheny; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Ebola Virus Disease, Marburg Virus Disease
Interventions: cAd3-Marburg, cAd3-EBO-S; Biological
Lead sponsor: Albert B. Sabin Vaccine Institute; Other
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Ovarian Cancer
Interventions: TUB-040 + Carbo + BEV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Los Angeles, California • East Brunswick, New Jersey • New York, New York

Conditions: Type 1 Diabetes
Interventions: AZD1656; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Duchenne Muscular Dystrophy
Interventions: HT-100; Drug
Lead sponsor: Processa Pharmaceuticals; Industry
Eligibility: 6 Years to 20 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Sacramento, California • Baltimore, Maryland • St Louis, Missouri + 2 more

Conditions: Healthy
Interventions: Inosine; Drug
Lead sponsor: Michael Alan Schwarzschild; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Healthy
Interventions: Oxycodone; Drug
Lead sponsor: Pain Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 2
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: MK-8591A, Islatravir, Doravine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Obstructive Sleep Apnea
Interventions: AD109, Atomoxetine, R-oxybutynin, Placebo, Digit System Substitution Test; Drug · Diagnostic Test
Lead sponsor: Apnimed; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Little Rock, Arkansas • Pomona, California • New Haven, Connecticut + 4 more

Search by objective public record fields.

A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

Effect of Number of Remote Limb Ischemic Conditioning Cycles on Learning Enhancement

Aerobic and Strengthening Exercise for Acute Leukemia

Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4

A Study of [¹⁴C]-LY3484356 in Healthy Female Participants

Point of Care 3D Ultrasound for Various Applications: A Pilot Study

A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)

Paced Electrocardiogram Requiring Fast Emergent Coronary Therapy (PERFECT) Study

Pharmacokinetic and Comparative Bioavailability Study of Codeine Sulfate Under Fasted Conditions

Lantus in Prediabetes

Swift Outpatient Alternatives for Rapid Stabilization

Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

VNS Algorithm for Advanced Dosing

Lipid Challenge in Adults

Egg Freezing Pilot Study

hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer

To Evaluate the Bioavailability of a Tablet of AZD1656

Open Label Extension Study of HT-100 in Patients With DMD

A Food-Drug Interaction Study of Serum Urate After Oral Inosine

Effects of Food on Oxycodone Pharmacokinetics in Healthy Volunteers

A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055)

Crossover Trial of AD109 in Obstructive Sleep Apnea